Advertisement
Advertisement

TARS

TARS logo

Tarsus Pharmaceuticals, Inc. Common Stock

59.15
USD
Sponsored
-4.99
-7.78%
Jul 10, 14:42 UTC -4
Open

TARS Earnings Reports

Positive Surprise Ratio

TARS beat 16 of 23 last estimates.

70%

Next Report

Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$170.71M
/
-$0.26
Implied change from Q1 26 (Revenue/ EPS)
+17.42%
/
+62.50%
Implied change from Q2 25 (Revenue/ EPS)
+66.28%
/
-45.83%

Tarsus Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On May 06, 2026, TARS reported earnings of -0.16 USD per share (EPS) for Q1 26, beating the estimate of -0.37 USD, resulting in a 57.65% surprise. Revenue reached 145.39 million, compared to an expected 150.67 million, with a -3.51% difference. The market reacted with a -1.24% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.26 USD, with revenue projected to reach 170.71 million USD, implying an increase of 62.50% EPS, and increase of 17.42% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Replimune Group, Inc.
Report Date
Jun 29, 2026 For Q4 26
Estimate
-$0.72
Actual
-$0.76
Surprise
-4.52%
logo
Beyond Air, Inc. Common Stock
Report Date
Jun 26, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.63
Surprise
-9.00%
FAQ
For Q1 2026, Tarsus Pharmaceuticals, Inc. Common Stock reported EPS of -$0.16, beating estimates by 57.65%, and revenue of $145.39M, -3.51% below expectations.
The stock price moved down -1.24%, changed from $64.76 before the earnings release to $63.96 the day after.
The next earning report is scheduled for Aug 06, 2026.
Based on 7 analysts, Tarsus Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.26 and revenue of $170.71M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement